Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC424 With or Without Azacitidine in Post-MPD AML or CMML
DRKS00007802Phase 2Terminated
- Sponsor
- Leipzig University
- Start
- Feb 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, azacitidine in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), sponsored by Leipzig University. Started Feb 2015; status: terminated.
02
Drugs
ruxolitinibazacitidine
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on DRKS00007802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00007802.